Joseph R. Winer

Joseph R. Winer

Auto-generated profile, based on publicly available information

Joseph R. Winer

Stanford University School of Medicine, Stanford, CA USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in The Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
JWJoseph R. Winer
Joseph R. Winer
BMBryce A. Mander
Bryce A. Mander
RHRandolph F. Helfrich
Randolph F. Helfrich
AMAnne Maass
Anne Maass
THTheresa M. Harrison
Theresa M. Harrison
MWMatthew P. Walker
Matthew P. Walker
Recent proposals suggest that sleep may be a factor associated with accumulation of two core pathological features of Alzheimer9s disease (AD): tau and β-amyloid (Aβ). Here we combined PET measures of Aβ and tau, electroencephalogram sleep recordings, and retrospective sleep evaluations to investigate the potential utility of sleep measures in predicting in vivo AD pathology in male and female older adults. Regression analyses revealed that the severity of impaired slow oscillation-sleep spindle coupling predicted greater medial temporal lobe tau burden. Aβ burden was not associated with coupling impairment but instead predicted the diminished amplitude of <1 Hz slow-wave-activity, results that were statistically dissociable from each other. Additionally, comparisons of AD pathology and retrospective, self-reported changes in sleep duration demonstrated that changes in sleep across the lifespan can predict late-life Aβ and tau burden. Thus, quantitative and qualitative features of human sleep represent potential noninvasive, cost-effective, and scalable biomarkers (current and future forecasting) of AD pathology, and carry both therapeutic and public health implications. SIGNIFICANCE STATEMENT Several studies have linked sleep disruption to the progression of Alzheimer9s disease (AD). Tau and β-amyloid (Aβ), the primary pathological features of AD, are associated with both objective and subjective changes in sleep. However, it remains unknown whether late life tau and Aβ burden are associated with distinct impairments in sleep physiology or changes in sleep across the lifespan. Using polysomnography, retrospective questionnaires, and tau- and Aβ-specific PET, the present study reveals human sleep signatures that dissociably predict levels of brain tau and Aβ in older adults. These results suggest that a night of polysomnography may aid in evaluating tau and Aβ burden, and that treating sleep deficiencies within decade-specific time windows may serve in delaying AD progression.

30 August 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
JWJoseph R. Winer
Joseph R. Winer
KDKacie D. Deters
Kacie D. Deters
GKGabriel Kennedy
Gabriel Kennedy
MJMeghan Jin
Meghan Jin
AGAndrea Goldstein-Piekarski
Andrea Goldstein-Piekarski
EMElizabeth C. Mormino
Elizabeth C. Mormino
Aging is associated with robust changes in sleep, resulting from shifts in lifestyle and underlying neurophysiological mechanisms.1 These changes are not uniform but instead heterogeneous, with variability in sleep architecture among older adults observed even in the absence of disease.2,3 Sleep health has important consequences for aging trajectories, and sleep disruption has been associated with increased risk of depression,4,5 cognitive decline,6,7 Alzheimer disease (AD),8,9 and cardiovascular and metabolic outcomes.10,11 Because poor sleep represents a potentially modifiable risk factor, it is critical to identify cognitive and biological correlates of sleep disturbance in the context of healthy aging.

3 September 2020 in Current Biology
Verified
Journal Article
Closed access
JWJoseph R. Winer
Joseph R. Winer
BMBryce A. Mander
Bryce A. Mander
SKSamika Kumar
Samika Kumar
MRMark Reed
Mark Reed
SBSuzanne L. Baker
Suzanne L. Baker
MWMatthew P. Walker
Matthew P. Walker

1 February 2018 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
JWJoseph R. Winer
Joseph R. Winer
AMAnne Maass
Anne Maass
PPPeter Pressman
Peter Pressman
JSJordan Stiver
Jordan Stiver
DSDaniel R. Schonhaut
Daniel R. Schonhaut
WJWilliam J. Jagust
William J. Jagust
Mild cognitive impairment is estimated to affect approximately 25% to 30% of patients with Parkinson disease (PD).1 Postmortem studies suggest that cognitive decline in PD is related to the combined influence of α-synuclein (a protein associated with presynaptic terminal function and the regulation of dopamine), the development of Alzheimer disease (AD), and cerebrovascular factors.2,3 Work in animal and cellular models has demonstrated that a synergistic relationship between α-synuclein and AD might accelerate cognitive decline.4-7 Despite this evidence for the contribution of multiple disease processes to cognitive impairment in PD, recent studies using positron emission tomographic (PET) imaging to measure AD biomarkers in patients with PD have reported mixed findings.8-10

14 February 2024 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
JWJoseph R. Winer
Joseph R. Winer
RLRenske Lok
Renske Lok
LWLara Weed
Lara Weed
ZHZihuai He
Zihuai He
KPKathleen L. Poston
Kathleen L. Poston
JZJamie M. Zeitzer
Jamie M. Zeitzer
Background: Sleep-wake regulating circuits are affected during prodromal stages in the pathological progression of both Alzheimer’s disease (AD) and Parkinson’s disease (PD), and this disturbance can be measured passively using wearable devices. Our objective was to determine whether accelerometer-based measures of 24-h activity are associated with subsequent development of AD, PD, and cognitive decline. Methods: This study obtained UK Biobank data from 82,829 individuals with wrist-worn accelerometer data aged 40 to 79 years with a mean (± SD) follow-up of 6.8 (± 0.9) years. Outcomes were accelerometer-derived measures of 24-h activity (derived by cosinor, nonparametric, and functional principal component methods), incident AD and PD diagnosis (obtained through hospitalization or primary care records), and prospective longitudinal cognitive testing. Results: One hundred eighty-seven individuals progressed to AD and 265 to PD. Interdaily stability (a measure of regularity, hazard ratio [HR] per SD increase 1.25, 95% confidence interval [CI] 1.05–1.48), diurnal amplitude (HR 0.79, CI 0.65–0.96), mesor (mean activity; HR 0.77, CI 0.59–0.998), and activity during most active 10 h (HR 0.75, CI 0.61–0.94), were associated with risk of AD. Diurnal amplitude (HR 0.28, CI 0.23–0.34), mesor (HR 0.13, CI 0.10–0.16), activity during least active 5 h (HR 0.24, CI 0.08–0.69), and activity during most active 10 h (HR 0.20, CI 0.16–0.25) were associated with risk of PD. Several measures were additionally predictive of longitudinal cognitive test performance. Conclusions: In this community-based longitudinal study, accelerometer-derived metrics were associated with elevated risk of AD, PD, and accelerated cognitive decline. These findings suggest 24-h rhythm integrity, as measured by affordable, non-invasive wearable devices, may serve as a scalable early marker of neurodegenerative disease.

21 July 2021 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JWJoseph R. Winer
Joseph R. Winer
AMAllison Morehouse
Allison Morehouse
LFLaura Fenton
Laura Fenton
THTheresa M. Harrison
Theresa M. Harrison
LALylian Ayangma
Lylian Ayangma
MWMatthew P. Walker
Matthew P. Walker
Alzheimer9s disease is associated with poor sleep, but the impact of tau and β-amyloid (Aβ) pathology on sleep remains largely unknown. Here, we test the hypothesis that tau and Aβ predict unique impairments in objective and self-perceived human sleep under real-life, free-living conditions. Eighty-nine male and female cognitively healthy older adults received 18F-FTP-tau and 11C-PIB-Aβ PET imaging, 7 nights of sleep actigraphy and questionnaire measures, and neurocognitive assessment. Tau burden, but not Aβ, was associated with markedly worse objective sleep. In contrast, Aβ and tau were associated with worse self-reported sleep quality. Of clinical relevance, Aβ burden predicted a unique perceptual mismatch between objective and subject sleep evaluation, with individuals underestimating their sleep. The magnitude of this mismatch was further predicted by worse executive function. Thus, early-stage tau and Aβ deposition are linked with distinct phenotypes of real-world sleep impairment, one that includes a cognitive misperception of their own sleep health. SIGNIFICANCE STATEMENT Alzheimer9s disease is associated with sleep disruption, often before significant memory decline. Thus, real-life patterns of sleep behavior have the potential to serve as a window into early disease progression. In 89 cognitive healthy older adults, we found that tau burden was associated with worse wristwatch actigraphy-measured sleep quality, and that both tau and β-amyloid were independently predictive of self-reported sleep quality. Furthermore, individuals with greater β-amyloid deposition were more likely to underestimate their sleep quality, and sleep quality underestimation was associated with worse executive function. These data support the role of sleep impairment as a key marker of early Alzheimer9s disease, and offer the possibility that actigraphy may be an affordable and scalable tool in quantifying Alzheimer9s disease-related behavioral changes.